AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01516294 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Iray
Description: The Oraya IRay stereotactic radiotherapy device will be used to deliver a 16 Gy dose of radiation to the macula. The radiotherapy will be delivered in a single session utilizing three sequential beams, each depositing 5.3 Gy at the macula through calculated scleral entry points, crossing the pars plana region of the eye, and overlapping at the same region of the macula.
Study NCT02927015 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White potato chips
Description: White potato chips
Study NCT02927015 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Crackers
Description: Crackers
Study NCT03848884 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence monitoring and education
Description: Standardized medication counseling and education combined with individual patient customized guidance and counseling - administered monthly.
Study NCT03231969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bilastine 0.2%
Description: 1 drop in each eye at 3 separate times during a 25 day period.
Study NCT03231969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bilastine 0.4%
Description: 1 drop in each eye at 3 separate times during a 25 day period.
Study NCT03231969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bilastine 0.6%
Description: 1 drop in each eye at 3 separate times during a 25 day period.
Study NCT03231969 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bilastine 0%
Description: 1 drop in each eye at 3 separate times during a 25 day period.
Study NCT01434745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin will be administered as a powder mixed with lactose at the dose of 0.5 mg/kg/day
Study NCT01434745 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lactose
Description: Lactose will be administered in a capsule formula.
Study NCT01772563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: volasertib
Description: Solution for infusion
Study NCT01772563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: itraconazole
Description: capsules
Study NCT03630263 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Raw Corn Starch
Description: Raw corn starch (30 g) will be added to 200 g of applesauce and served to participants, gastric emptying rate, and postprandial glucose will be measured.
Study NCT03630263 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Raw Corn Starch
Description: 200 g of applesauce will be consumed and gastric emptying rate, and postprandial glucose will be measured.
Study NCT05531071 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biofeedback electrical stimulation
Description: treated with biofeedback electrical stimulation, 3 times a week for 30 minutes for 15 times.
Study NCT05531071 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: acupuncture treatment, including Guanyuan, Qihai, Zhongji, Zusanli, Sanyinjiao and Yinlingquan, once a day, Monday to Friday, 30 minutes each, a total of 10 times.
Study NCT05531071 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with biofeedback electrical stimulation
Description: treated with acupuncture combined with biofeedback electrical stimulation.
Study NCT02250690 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: experimental group - tDCS
Study NCT02250690 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control group (tDCS sham)
Study NCT03003806 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DreaMed Advisor Pro
Description: Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the DreaMed Advisor Pro
Study NCT03003806 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical guided recommendation
Description: Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted by the medical team
Study NCT04380428 — intervention group
Intervention type: OTHER
Intervention: No Intervention. Observational study.
Description: No Intervention. Observational study.
Study NCT00519545 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prayer
Description: Data collection on physiological biomarkers
Study NCT01322009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probenecid and N-acetyl cysteine
Description: After obtaining written parental consent, patients will be randomized by the use of a blind envelope system to one of the following: to receive probenecid (initial: 25 mg/kg/dose; maintenance: 10mg/kg/dose 4 x per day for 11 doses) and NAC (initial: 140mg/kg/dose; maintenance: 70mg/kg/dose 6 x per day for 17 doses) or the placebo via nasogastric (NG) or orogastric (OG) tube for 3 days or to receive placebos.
Study NCT01322009 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After obtaining written parental consent, patients will be randomized by the use of a blind envelope system to one of the following: to receive probenecid (initial: 25 mg/kg/dose; maintenance: 10mg/kg/dose 4 x per day for 11 doses) and NAC (initial: 140mg/kg/dose; maintenance: 70mg/kg/dose 6 x per day for 17 doses) or the placebo via nasogastric (NG) or orogastric (OG) tube for 3 days. Placebo contents include equal volumes and dosing regimens of lactose powder (for opacity) suspended in Ora-Plus and normal saline.
Study NCT01408810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: 5 mg/Kg, I.V. at weeks 0, 2, 6 and every 8 weeks thereafter
Study NCT01265004 — intervention group
Intervention type: PROCEDURE
Intervention: Stitches
Description: Surgical treatment of a rupture of the achilles tendon, in which both end are fastened with a U-forming stitching
Study NCT01265004 — intervention group
Intervention type: PROCEDURE
Intervention: Fibrin-glue
Description: Surgical treatment, in which both ends are glued together using a medical fibrin-containing glue
Study NCT00074295 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GVAX lung cancer vaccine
Description: 6-7 injections per week in rotating locations for five weeks
Study NCT00034554 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp75 DNA vaccine
Description: 6 patients will be enrolled in each of the 5 vaccination groups. Patients in vaccination groups 1-3 will receive a total of 5(1 mL) vaccinations. Patients assigned to vaccination group 4 will receive a total of 5 (2.0 mL) vaccinations administered as 2 1 mL injections. Patients assigned to vaccination group 5 will receive a total of 5 (4.0 mL or 8.0 mg)vaccinations administered as 4 1 mL injections per vaccination treatment Patients will receive gp75 DNA vaccinations every 3 weeks for 5 vaccinations. Injection sites will be given intramuscularly and rotated for each dose using all 4 limbs with the exception of a site that had the removal of lymph nodes. Progression to next higher dose level will be based on the 5\* patient safely completing the 2nd vaccination at the lower dose level.
Study NCT02493465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Conversion from azathioprine to everolimus in kidneys transplant recipients with left ventricular hypertrophy.
Study NCT01196819 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Firehawk
Description: Implantation of Firehawk drug eluting stent
Study NCT01196819 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xience V
Description: Implantation of Xience V drug eluting stent
Study NCT01265004 — intervention group
Intervention type: PROCEDURE
Intervention: Stitches and Fibrin-glue
Description: Surgical treatment, in which both ends of the ruptured tendon are fastened together with u-forming stitches as well as fibrin-glue
Study NCT03630133 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intracept System Ablation
Description: Radiofrequency ablation using Intracept System
Study NCT02708030 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ketogenic Diet
Description: The children with the drug resistant epilepsy will go through a run in period of 4 weeks during which each child will undergo a detailed detailed clinical evaluation according to a structured proforma, and baseline investigations. The patients in KD arm will be admitted to the hospital for initiation of diet.
Study NCT02708030 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MAD
Description: The children with the drug resistant epilepsy will go through a run in period of 4 weeks during which each child will undergo a detailed detailed clinical evaluation according to a structured proforma, and baseline investigations. Following the run in period of 4 weeks, the patients will be randomized to the MAD or LGIT or KD arm. MAD will be initiated on out patient basis.
Study NCT04394195 — intervention group
Intervention type: OTHER
Intervention: measurement of circulating sFlt1 concentration
Description: blood circulating sFlt1 concentration will be determined
Study NCT02708030 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LGIT
Description: The children with the drug resistant epilepsy will go through a run in period of 4 weeks during which each child will undergo a detailed detailed clinical evaluation according to a structured proforma, and baseline investigations. Following the run in period of 4 weeks, the patients will be randomized to the MAD or LGIT or KD arm. LGIT will be initiated on out patient basis.
Study NCT03945643 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: 50mg administration of sildenafil, one time, one hour prior to measurements.
Study NCT02034760 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Heavy Resistance Training
Description: Supervised Heavy Resistance Training three times weekly for 52 weeks.
Study NCT02034760 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Light Intensity Training
Description: Home-based Light Intensity Training three-five times weekly for 52 weeks.
Study NCT02034760 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein Whey
Description: Two daily 20g whey protein and 10g carbohydrate supplementations for 52 weeks.
Study NCT02034760 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein Whey
Description: Two daily 20g whey protein and 10g carbohydrate supplementations for 52 weeks.
Study NCT02034760 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein Collagen
Description: Two daily 20g collagen protein and 10g carbohydrate supplementations for 52 weeks.
Study NCT02034760 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Carbohydrate
Description: Two daily 30g carbohydrate supplementations for 52 weeks.
Study NCT03488602 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: F-SPS+UC
Description: Manualized individual and family program. Weekly individual and family sessions with a therapist for 6 weeks.~Participants will continue to receive usual care.
Study NCT03488602 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EUC
Description: Weekly telephone contact with parents regarding participant health care utilization. Referrals to community mental health resources provided as needed.~Participants will continue to receive usual care.
Study NCT05589402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Cream 5%
Description: Ebanel 5% Lidocaine Topical Numbing Cream Maximum Strength 1.35 Oz, Numb520 Pain Relief Cream Anesthetic Cream Infused with Aloe Vera, Vitamin E, Lecithin, Allantoin, Secured with Child Resistant Cap
Study NCT05589402 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Rehabilitation Movement Training
Description: reaching tasks, hand exercises (e.g., putty, grip exerciser, resistance bands, etc).
Study NCT03309345 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention as this is an observational study investigates the difference between PKU ant matched healthy control in terms of energy components and dietary intake
Study NCT02981732 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liuwei Dihuang Pill
Study NCT00298363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (tenofovir DF; TDF)
Description: 300-mg tablet QD
Study NCT00298363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)
Description: FTC 200 mg/TDF 300 mg fixed-dose combination (FDC) tablet QD
Study NCT00298363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir (ETV)
Description: 0.5-mg or 1-mg tablet QD
Study NCT00298363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF placebo
Description: Placebo to match TDF QD
Study NCT00298363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/TDF placebo
Description: Placebo to match FTC/TDF QD
Study NCT00298363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETV placebo
Description: Placebo to match ETV QD
Study NCT04191343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab injection combined with GEMOX
Description: Toripalimab Injection (240mg, intravenous drip, d1, q3w);Combined with gemcitabine (1000mg/m2, intravenous drip, d1, d8, q3w) and oxaliplatin (100mg/m2, intravenous drip, d1, q3w)
Study NCT05742113 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Masimo Radical-7
Description: perfusion index measuring device
Study NCT03323970 — intervention group
Intervention type: OTHER
Intervention: semi-structured interviews
Description: individual semi-structured interviews
Study NCT03105856 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CERVARIX
Description: - HPV16/18 L1 VLP AS04 vaccine (Cervarix®) group according to a two-dose schedule (0-12 month). This group will receive the HPV16/18 vaccine containing HPV16 and HPV18 L1 virus-like-particles (20 μg of each) adjuvanted with 50 μg 3-O-desacyl-4'-monophosphoryl lipid A and 0.5 mg aluminum hydroxide (GlaxoSmithKline Biologicals, Rixensart, Belgium). A 0.5-mL dose of the vaccine will be administered in the non-dominant arm.
Study NCT03105856 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GARDASIL
Description: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) (Gardasil®) recombinant vaccine according to a two dose schedule (0-12 month). This group will receive amorphous aluminum hydroxyphosphate sulfate adjuvanted quadrivalent HPV (types 6, 11, 16, 18) L1 VLP vaccine (Merck Sharp \& Dohme Corp. Whitehouse Station, NJ, USA). A 0.5-mL dose of the vaccine will be administered in the non-dominant arm.
Study NCT03955900 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Both retrospective and prospective data will be collected. The retrospective data will be collected through medical chart review.
Study NCT00135356 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir (ATV) + ritonavir (RTV), continuation of backbone 2 nucleoside reverse transcriptase inhibitor (NRTIs)
Description: Capsules, Oral, ATV 300 mg + RTV 100 mg once daily up to 96 weeks
Study NCT00135356 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: continuation of current HAART (boosted protease inhibitor [PI] combination + 2 NRTIs)
Description: Protease inhibitor \[PI\] combination + 2 NRTIs
Study NCT00153816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Carbonate
Description: 3 gm/daily; 1200 mg elemental calcium/daily; two tablets per day; 600 mg elemental calcium/tablet
Study NCT00153816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 1000 IU/daily; two tablets per day; 500 IU per tablet
Study NCT00153816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo; two tablets per day
Study NCT02222116 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MGuard Prime
Study NCT02222116 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control BMS DES
Study NCT04823806 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Spermidine (spermidineLIFE ®) OR Placebo
Description: 21 day of 6mg spermidine OR Placebo supplementation per day
Study NCT03945643 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50mg administration in gel-encapsulated microcrystalline cellulose one time, one hour prior to measurements.
Study NCT02938897 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Registered Dietitian Nutritionist (RDN) Support
Description: RDN provided individualized medical nutrition therapy via videoconference at weeks 1, 5, and 9 and telephonic nutrition coaching support at weeks 2-4, 6-8, and 10-12.
Study NCT02938897 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet-related educational materials
Description: Individualized caloric recommendations (500-750 kcal reduction) were made and food-based educational materials emphasizing general healthful eating patterns and increased intakes of nutrient-rich foods were provided.
Study NCT02938897 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet-related educational materials
Description: Individualized caloric recommendations (500-750 kcal reduction) were made and food-based educational materials emphasizing general healthful eating patterns and increased intakes of nutrient-rich foods were provided.
Study NCT02938897 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-monitoring tools
Description: Self-monitoring tools including: weekly weight log, fruit and vegetable tracker, and a SMART (specific, measurable, achievable, relevant, and time bound) goal planner were provided.
Study NCT02938897 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-monitoring tools
Description: Self-monitoring tools including: weekly weight log, fruit and vegetable tracker, and a SMART (specific, measurable, achievable, relevant, and time bound) goal planner were provided.
Study NCT05906797 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal treatment
Description: Subgingival biofilm ultrasonic debridement
Study NCT01130649 — intervention group
Intervention type: DEVICE
Intervention: HealthBuddy
Description: Noninvasive device for remotely reporting health information. The device does nothing to change the health of the patient, but transmits health data that is entered by the patient directly to the physician's office. Patients will enter data on seizure frequency, medication compliance, and side effects.
Study NCT00952848 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Pain Rating Score
Study NCT00952848 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensory Neuropathy Scale instrument
Description: ECOG Common Toxicity Criteria for Sensory Neuropathy scale
Study NCT00952848 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of Life instrument
Description: Uniscale 0-100 scale global quality of life
Study NCT00952848 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MC5-A Scrambler device
Description: Electrical stimulation for 60 minutes
Study NCT00830609 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa 2 A
Description: Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 800 mg/day po (Control Group) Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 1,600 mg/day po plus Epoetin β (450 IU/kg/week) SC over 4 weeks (Arm B1) Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 1,600 mg/day po plus Epo beta 450 UI over four weeks (Arm B1) If RNA-HCV positive at week 4, Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 1,600 mg/day plus Epo beta 450 UI to keep Hb>12 g/dL if required over 20 additional weeks (Arm B2)
Study NCT00830609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa 2 A
Description: Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 800 mg/day po (Control Group) Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 1,600 mg/day po plus Epoetin β (450 IU/kg/week) SC over 4 weeks (Arm B1) Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 1,600 mg/day po plus Epo beta 450 UI over four weeks (Arm B1) If RNA-HCV positive at week 4, Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 1,600 mg/day plus Epo beta 450 UI to keep Hb>12 g/dL if required over 20 additional weeks (Arm B2)
Study NCT00830609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa 2 A, ribavirin + Epo Beta
Description: Ribavirin 1,600 mg/day plus peginterferon alfa 2A 180 mcg/week plus Epo beta 450 IU/Kg/day to maintain Hb>12g/dl over 4 or 24 weeks
Study NCT00830609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: RBV 1600 mg/day 24 weeks
Study NCT00830609 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ribavirin
Description: ribavirin 800 mg/day for 24 weeks
Study NCT00830609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa 2
Description: Peginterferon alfa 2 a 180 mcg/week for 4 weeks and then peginterferon alfa 2A for 20 weeks
Study NCT00830609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: RBV 1600 mg/day 4 weeks and then ribavirin 800 mg/day 20 weeks
Study NCT00755417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin Extended-Release (G-ER) 1200 mg
Description: G-ER 1200 mg daily dosage given as two 600-mg tablets.